Features of occult hepatitis B diagnostics in cancer patients
Purpose of the study. Analysis of the frequency of detection of HBsAg-negative hepatitis B serological and molecular biological markers in cancer patients.Materials and methods. The blood serum samples of patients hospitalized at the National Medical Research Centre for Oncology in 2016–2023 were s...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ANO "Perspective of oncology"
2025-03-01
|
| Series: | Южно-Российский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.cancersp.com/jour/article/view/295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849244461370966016 |
|---|---|
| author | E. A. Shevyakova T. A. Zykova L. A. Velikorodnaya A. V. Shaposhnikov |
| author_facet | E. A. Shevyakova T. A. Zykova L. A. Velikorodnaya A. V. Shaposhnikov |
| author_sort | E. A. Shevyakova |
| collection | DOAJ |
| description | Purpose of the study. Analysis of the frequency of detection of HBsAg-negative hepatitis B serological and molecular biological markers in cancer patients.Materials and methods. The blood serum samples of patients hospitalized at the National Medical Research Centre for Oncology in 2016–2023 were studied. 41,523 samples were tested for HBsAg, 2,035 for anti-HBcore, of which 958 were tested simultaneously for both markers using the enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA). 1,380 samples were tested for the presence of hepatitis B virus (HBV) DNA in blood plasma using real time polymerase chain reaction (qPCR).Results. The HBsAg prevalence in cancer patients accounted for 2.5 % (1051/41523), 23.7 % (483/2035) for anti-HBcore. Simultaneous examination for HBsAg and anti-HBcore revealed various combinations of markers. Among HBV-positive variants, the most common was the combination anti-HBcore+HBsAg-. The average number of such patients was 20.6 % (197/958). The simultaneous presence of both markers was noted in 4.6 % of patients (44/958). There were no isolated HBsAg detection cases. The total number of HBV+ individuals was 25.2 % (241/958). 81.7 % out of these (197/241) were HBsAg-negative.219 samples with the HBV DNA presence in the blood plasma were identified. 19 of these were examined simultaneously for HBsAg, anti-HBcore. The majority (78.9 %) had all three markers. 21.1 % were HBsAg-negative but DNA-positive (latent form of infection), 15.8 % of which were anti-HBcore-positive, and 5.3 % did not have a single serological marker.Conclusion. The detection of anti-HBcore in the absence of HBsAg can indicate the presence of occult forms of hepatitis B, which under conditions of drug immunosuppression can be reactivated. The identified significant percentage of cancer patients with occult hepatitis B variants highlights the necessity to expand the number of diagnostic markers for screening. Additional testing for anti-HBcore can significantly increase the likelihood of detecting HBV during prehospital testing. |
| format | Article |
| id | doaj-art-9f07f1bd1131465d9c9888e3edb90435 |
| institution | Kabale University |
| issn | 2686-9039 |
| language | Russian |
| publishDate | 2025-03-01 |
| publisher | ANO "Perspective of oncology" |
| record_format | Article |
| series | Южно-Российский онкологический журнал |
| spelling | doaj-art-9f07f1bd1131465d9c9888e3edb904352025-08-20T03:59:09ZrusANO "Perspective of oncology"Южно-Российский онкологический журнал2686-90392025-03-016161410.37748/2686-9039-2025-6-1-1175Features of occult hepatitis B diagnostics in cancer patientsE. A. Shevyakova0T. A. Zykova1L. A. Velikorodnaya2A. V. Shaposhnikov3National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyPurpose of the study. Analysis of the frequency of detection of HBsAg-negative hepatitis B serological and molecular biological markers in cancer patients.Materials and methods. The blood serum samples of patients hospitalized at the National Medical Research Centre for Oncology in 2016–2023 were studied. 41,523 samples were tested for HBsAg, 2,035 for anti-HBcore, of which 958 were tested simultaneously for both markers using the enzyme-linked immunosorbent assay (ELISA) or chemiluminescent immunoassay (CLIA). 1,380 samples were tested for the presence of hepatitis B virus (HBV) DNA in blood plasma using real time polymerase chain reaction (qPCR).Results. The HBsAg prevalence in cancer patients accounted for 2.5 % (1051/41523), 23.7 % (483/2035) for anti-HBcore. Simultaneous examination for HBsAg and anti-HBcore revealed various combinations of markers. Among HBV-positive variants, the most common was the combination anti-HBcore+HBsAg-. The average number of such patients was 20.6 % (197/958). The simultaneous presence of both markers was noted in 4.6 % of patients (44/958). There were no isolated HBsAg detection cases. The total number of HBV+ individuals was 25.2 % (241/958). 81.7 % out of these (197/241) were HBsAg-negative.219 samples with the HBV DNA presence in the blood plasma were identified. 19 of these were examined simultaneously for HBsAg, anti-HBcore. The majority (78.9 %) had all three markers. 21.1 % were HBsAg-negative but DNA-positive (latent form of infection), 15.8 % of which were anti-HBcore-positive, and 5.3 % did not have a single serological marker.Conclusion. The detection of anti-HBcore in the absence of HBsAg can indicate the presence of occult forms of hepatitis B, which under conditions of drug immunosuppression can be reactivated. The identified significant percentage of cancer patients with occult hepatitis B variants highlights the necessity to expand the number of diagnostic markers for screening. Additional testing for anti-HBcore can significantly increase the likelihood of detecting HBV during prehospital testing.https://www.cancersp.com/jour/article/view/295occult viral hepatitis bhbv reactivationoncological diseases |
| spellingShingle | E. A. Shevyakova T. A. Zykova L. A. Velikorodnaya A. V. Shaposhnikov Features of occult hepatitis B diagnostics in cancer patients Южно-Российский онкологический журнал occult viral hepatitis b hbv reactivation oncological diseases |
| title | Features of occult hepatitis B diagnostics in cancer patients |
| title_full | Features of occult hepatitis B diagnostics in cancer patients |
| title_fullStr | Features of occult hepatitis B diagnostics in cancer patients |
| title_full_unstemmed | Features of occult hepatitis B diagnostics in cancer patients |
| title_short | Features of occult hepatitis B diagnostics in cancer patients |
| title_sort | features of occult hepatitis b diagnostics in cancer patients |
| topic | occult viral hepatitis b hbv reactivation oncological diseases |
| url | https://www.cancersp.com/jour/article/view/295 |
| work_keys_str_mv | AT eashevyakova featuresofocculthepatitisbdiagnosticsincancerpatients AT tazykova featuresofocculthepatitisbdiagnosticsincancerpatients AT lavelikorodnaya featuresofocculthepatitisbdiagnosticsincancerpatients AT avshaposhnikov featuresofocculthepatitisbdiagnosticsincancerpatients |